.jpg)
Christine Lee, PharmD, Ph.D.
Christine Lee received her PharmD from the University of Buffalo and her PHD in Pharmaceutical Outcomes and Policy from the University of Florida. Dr. Lee is an expert in social and behavioral sciences, decision analysis, and human behavioral theories. She is also classically trained in measurement, psychometrics, focus group testing and outcome analysis.
She is a leader in driving national impact in reducing adverse drug events across the healthcare industry, an expert in coalition-building and partnership development within public and private
sectors and an expert in translating quantitative and qualitative research to drive informed policy, educational interventions and communication strategies.
Dr. Christine Lee serves as the Lead for Strategic Research Engagement for the Office of Minority Health and Health Equity (OMHHE) in the Office of the Commissioner at the U.S. Food and Drug Administration. She leads minority health and health equity focused research and develops strategic partnerships to advance the health of diverse populations. Prior to joining OMHHE, Dr. Lee’s work included structuring unstructured FDA materials as well as social media data to inform regulatory decision making. Dr. Lee aims to develop research and strategic innovations that advance the health for all populations.
Abstract: Leveraging research and collaboration to advance
health equity
The mission of the FDA Office of Minority Health and Health Equity to promote and protect the health of diverse populations through research and communication of science that addresses health disparities. The presentation will focus on describing FDA OMHHE’s programmatic efforts for the following areas: (1) EQUITY in clinical trials: supporting efforts to advance diversity in clinical trials; (2) EQUITABLE data efforts : increasing data available on diverse groups including, but not limited to, ethnicity, race, age, disability and geography; and (3) EQUITY of voices : amplifying FDA’s communication with diverse groups and to ensure stakeholders, including consumers, are informed about FDA’s efforts and to understand diverse patient perspectives, preferences and unmet needs.